- Record: found
- Abstract: found
- Article: found
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
Giacomo Frosi
1 ,
Alessia Biolchi ,
Morena Lo Sapio ,
Fabio Rigat ,
Stefanie Gilchrist ,
Jay Lucidarme ,
Jamie Findlow ,
Ray Borrow ,
Mariagrazia Pizza ,
Marzia Monica Giuliani ,
Duccio Medini
Oct 09 2013
4CMenB vaccine strain coverage,
CC,
ELISA,
FN,
FP,
HPA,
Health Protection Agency,
IMD,
MATS,
MLST,
MenB,
Meningococcal Antigen Typing System,
NHBA,
NadA,
Neisseria meningitidis serogroup B,
Neisserial adhesin A,
Neisserial heparin binding antigen,
OMV,
PBT,
PorA,
RP,
SBA,
ST,
Serum bactericidal antibody assay,
Stratified proportional sampling,
TN,
TP,
capsular group B meningococcus,
clonal complex,
enzyme-linked immunosorbent assay,
fHBP,
factor H binding protein,
false negatives,
false positives,
hSBA,
invasive meningococcal disease,
multilocus sequence typing,
outer membrane vesicle,
porin A,
positive bactericidal threshold,
relative potency,
sequence type,
serum bactericidal antibody,
serum bactericidal antibody assay with human complement,
true negatives,
true positives
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
4CMenB (Bexsero), a vaccine developed against invasive meningococcal disease caused by capsular group B strains (MenB), was recently licensed for use by the European Medicines Agency. Assessment of 4CMenB strain coverage in specific epidemiologic settings is of primary importance to predict vaccination impact on the burden of disease. The Meningococcal Antigen Typing System (MATS) was developed to predict 4CMenB strain coverage, using serum bactericidal antibody assay with human complement (hSBA) data from a diverse panel of strains not representative of any specific epidemiology.
Related collections
Author and article information
4CMenB vaccine strain coverage,CC,ELISA,FN,FP,HPA,Health Protection Agency,IMD,MATS,MLST,MenB,Meningococcal Antigen Typing System,NHBA,NadA,Neisseria meningitidis serogroup B,Neisserial adhesin A,Neisserial heparin binding antigen,OMV,PBT,PorA,RP,SBA,ST,Serum bactericidal antibody assay,Stratified proportional sampling,TN,TP,capsular group B meningococcus,clonal complex,enzyme-linked immunosorbent assay,fHBP,factor H binding protein,false negatives,false positives,hSBA,invasive meningococcal disease,multilocus sequence typing,outer membrane vesicle,porin A,positive bactericidal threshold,relative potency,sequence type,serum bactericidal antibody,serum bactericidal antibody assay with human complement,true negatives,true positives
4CMenB vaccine strain coverage, CC, ELISA, FN, FP, HPA, Health Protection Agency, IMD, MATS, MLST, MenB, Meningococcal Antigen Typing System, NHBA, NadA, Neisseria meningitidis serogroup B, Neisserial adhesin A, Neisserial heparin binding antigen, OMV, PBT, PorA, RP, SBA, ST, Serum bactericidal antibody assay, Stratified proportional sampling, TN, TP, capsular group B meningococcus, clonal complex, enzyme-linked immunosorbent assay, fHBP, factor H binding protein, false negatives, false positives, hSBA, invasive meningococcal disease, multilocus sequence typing, outer membrane vesicle, porin A, positive bactericidal threshold, relative potency, sequence type, serum bactericidal antibody, serum bactericidal antibody assay with human complement, true negatives, true positives